Among the biggest risers on the S&P 500 on Friday November 29 was Endo International plc ($ENDP), popping some 6.28% to a price of $5.08 a share with some 6.87 million shares trading hands.
Starting the day trading at $4.80, Endo International plc reached an intraday high of $5.16 and hit intraday lows of $4.73. Shares gained $0.3 apiece by day’s end. Over the last 90 days, the stock’s average daily volume has been n/a of its 223.1 million share total float. Today’s action puts the stock’s 50-day SMA at $n/a and 200-day SMA at $n/a with a 52-week range of $1.97 to $12.55.
After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The acquisitions of Auxilium and Par increased the company’s presence in urology and generics, respectively.
Endo International plc has its corporate headquarters located in Dublin, and employs 2,910 people. Its market cap has now risen to $1.15 billion after today’s trading, its P/E ratio is now n/a, its P/S n/a, P/B -1.74, and P/FCF n/a.
The Dow Jones Industrial Average (DJIA) is the most visible stock index in the United States, but that doesn’t make it the best. In fact, the industry standard for market watchers and institutional investors in gauging portfolio performance is the S&P 500.
The DJIA relies on just 30 stocks as a sample of large- and mega-cap firms, dwarfed by the 500 contained in the S&P 500, and it also weights its returns using an outdated and flawed price-weighting method. The S&P 500’s weighting is based on market cap, making it a much better representation of actual market performance for large- and mega-cap stocks.
